A court-imposed deadline falling on August 4, 2026 is about to reshape the trajectory of one of the most closely watched medical device litigations in the country. In MDL 3125 — formally titled AngioDynamics, Inc. and Navilyst Medical, Inc. Port Catheter Products Liability Litigation — both plaintiffs and defendants must each nominate nine bellwether cases by that date, creating an 18-case pool that will define how the entire litigation proceeds. For the 391 cancer patients already in the MDL, and potentially thousands more who were implanted with AngioDynamics SmartPort, Vortex Port, or Xcela devices and have no idea an AngioDynamics port catheter lawsuit even exists, the next few weeks are critical.
What Is MDL 3125 and Why Does It Matter Right Now
MDL 3125 was created in October 2024 in the Southern District of California before U.S. District Judge Jinsook Ohta. At the time of its creation, the MDL consolidated 56 individual actions. By June 2026, that number had climbed to 391 pending cases — a staggering 693% increase since the MDL’s formation, according to MDL Update tracking data. The case count rose from 375 in May 2026 to 391 in June 2026 alone, signaling that awareness of the litigation is accelerating rapidly among cancer patients and their families.
The procedural moment now approaching is the single most consequential development since the MDL was formed. Judge Ohta originally set June 5, 2026 as the bellwether selection deadline, but AngioDynamics requested a 60-day extension. The court granted that extension, pushing the deadline to August 4, 2026 — now less than three weeks away. Under the court’s scheduling order, each side must nominate exactly nine cases, with a specific injury breakdown: four infection-only cases, two thrombosis cases, two catheter fracture cases, and one case involving any qualifying injury other than wrongful death.
Plaintiff fact sheets for the selected bellwether cases were already due on July 15, 2026. Defendant fact sheets follow on September 1, 2026. By December 2026, the pool will be narrowed to eight cases. The first AngioDynamics bellwether trial is not expected until mid-2028. If you have been implanted with one of these devices and suffered a serious complication, understanding this timeline — and where you fit in — is urgent. Use a medical malpractice calculator to begin evaluating the potential value of a defective medical device claim while the litigation is still actively accepting new filings.
The Devices at the Center of the AngioDynamics Port Catheter Lawsuit
The AngioDynamics port catheter lawsuit targets three specific implanted port catheter products manufactured by AngioDynamics, Inc. and its subsidiary Navilyst Medical, Inc.:
- SmartPort CT Titanium Port — a titanium-bodied implantable port designed for high-pressure contrast CT injections, used widely in cancer chemotherapy delivery
- Vortex Port — a rounded reservoir port device also used for long-term intravenous access in chemotherapy patients
- Xcela Plus Port — marketed as a power-injectable port for chemotherapy and imaging contrast, implicated in thrombosis and fracture reports
These devices are implanted subcutaneously, typically in the chest, and connected to a catheter threaded into the superior vena cava. They allow nurses and oncology teams to deliver chemotherapy drugs, draw blood, and administer fluids without repeated needle sticks. Because patients using these devices are already immunocompromised from cancer treatment, any device failure carries an elevated risk of catastrophic or fatal consequences.
The FDA’s MAUDE database contains more than 500 adverse event reports linked to AngioDynamics port catheter products — a body of real-world safety data that plaintiffs argue demonstrates the company knew or should have known about recurring failure patterns well before litigation began.
Alleged Device Defects and Injury Types in MDL 3125
Catheter Fracture and Migration
The most structurally alarming allegation in the AngioDynamics port catheter lawsuit is that these catheters fracture spontaneously — either along the catheter body or at connection points between the catheter and the port reservoir. When fracture occurs, catheter fragments can enter the bloodstream and migrate through venous circulation to the heart or pulmonary arteries. Emergency surgical or interventional radiology retrieval procedures are often required, carrying their own serious procedural risks for already-ill cancer patients.
Court filings in MDL 3125 include an Illinois woman who alleged her SmartPort fractured and that a fragment migrated to her heart, requiring immediate surgery. An Oregon woman alleged her SmartPort caused a pulmonary embolism that was discovered only years after implantation. These fracture and migration cases are considered by mass tort attorneys to be among the strongest vehicles for plaintiff verdicts — a pattern supported by parallel litigation elsewhere, as discussed below.
Catheter-Related Bloodstream Infections and Sepsis
A second category of alleged harm involves catheter-related bloodstream infections, known clinically as CRBSIs. Plaintiffs allege that design or manufacturing defects in AngioDynamics port catheters create pathways for bacterial colonization and systemic infection. For cancer patients on chemotherapy — who often have severely suppressed white blood cell counts — a bloodstream infection that might be manageable in a healthy person can rapidly escalate to life-threatening sepsis. The MDL includes a wrongful death suit filed in January 2026 alleging that a Vortex port caused fatal sepsis, underscoring the stakes involved. Families navigating loss from a defective port device may want to consult a wrongful death calculator to understand the range of compensable damages in fatal mass tort cases.
Thrombosis
A third alleged injury type is venous thrombosis — dangerous blood clots forming at or around the implanted catheter tip. A Nevada woman’s case in MDL 3125 alleged her Xcela Plus Port caused thrombosis in her right internal jugular vein. CDC data on venous thromboembolism underscores that catheter-associated thrombosis is a recognized and serious clinical risk — one plaintiffs argue was amplified by alleged defects in AngioDynamics device design.
MDL 3125 vs. Bard PowerPort MDL 3081: A Critical Comparison
The AngioDynamics port catheter lawsuit does not exist in a vacuum. A closely watched parallel proceeding — Bard PowerPort MDL 3081 — has been litigating implantable port catheter defect claims against C.R. Bard in the District of Arizona before Judge David G. Campbell. As of July 2026, Bard’s MDL has 3,564 pending cases — substantially larger than AngioDynamics’ 391 — but the two litigations are teaching the legal community important lessons about trial strategy.
Bard’s first bellwether trial, Cook v. Bard, concluded on May 8, 2026 with a defense verdict on an infection-only case. Bard’s second scheduled bellwether plaintiff, Wanda Miller, died on February 2, 2026, leading the court to vacate that trial. The practical takeaway for observers of the AngioDynamics MDL: infection-only cases appear harder to win at trial than fracture or thrombosis cases, where device malfunction is more mechanically demonstrable. This dynamic likely influenced how Judge Ohta structured the injury-type requirements in MDL 3125’s bellwether pool — requiring a mix of case types so that the litigation is not artificially skewed toward either side’s strongest or weakest facts.
| Metric | MDL 3125 (AngioDynamics) | MDL 3081 (Bard PowerPort) |
|---|---|---|
| Court / Judge | S.D. California / Judge Ohta | D. Arizona / Judge Campbell |
| MDL Created | October 2024 | 2022 |
| Cases Pending (July 2026) | 391 | 3,564 |
| Case Growth Since MDL Creation | +693% | Significant ongoing growth |
| First Bellwether Result | Not yet tried (trial ~mid-2028) | Defense verdict (May 8, 2026) |
| Bellwether Selection Deadline | August 4, 2026 | Already completed |
| Settlement Status (July 2026) | No settlements announced | No global settlement announced |
| Devices at Issue | SmartPort, Vortex Port, Xcela Plus | Bard PowerPort |
| FDA MAUDE Adverse Events | 500+ reports | Substantial independent record |
| Expected Settlement Window | 2028–2029 at earliest | 2027–2028 (estimated) |
Sources: MDL Update case census data (June–July 2026); Southern District of California court records; FDA MAUDE database.
Who Qualifies to File an AngioDynamics Port Catheter Lawsuit
If you or a family member received cancer treatment or long-term intravenous therapy through an implanted port and experienced any of the following complications, you may have a qualifying claim in the AngioDynamics port catheter lawsuit:
- Catheter fracture, breakage, or fragmentation requiring surgical or interventional retrieval
- Fragment migration to the heart, pulmonary arteries, or elsewhere in the vascular system
- Catheter-related bloodstream infection (CRBSI) or sepsis requiring hospitalization
- Venous thrombosis or pulmonary embolism associated with the implanted port
- Wrongful death of a family member whose death was related to any of the above complications
The specific devices involved are the AngioDynamics/Navilyst SmartPort CT Titanium Port, Vortex Port, and Xcela Plus Port. If you are unsure which device was implanted, your surgical records, discharge paperwork, or implant card from the hospital where the procedure was performed will identify the manufacturer and model.
Statute of limitations rules are critically important here. Most states allow two to three years from the date you discovered — or reasonably should have discovered — that your injury was linked to the device. For patients whose catheter fractures or infections occurred years ago, the clock may already be running. The MDL directly accepts new case filings through its Case Management Order process. Use a personal injury settlement calculator to get an initial sense of potential case value before consulting an attorney.
What to Expect: Settlement Timeline and Next Steps
No settlements have been announced in MDL 3125 as of July 2026, and none are expected imminently. Mass tort MDL settlements of this type typically follow a predictable sequence: bellwether trials create a “settlement pressure” data point for defendants, who then negotiate a global resolution. Based on the current schedule — bellwether pool finalized by December 2026, first trial approximately mid-2028 — attorneys familiar with the litigation estimate that a global settlement is unlikely before 2028 to 2029 at the earliest.
That timeline may feel discouraging, but it carries an important implication for potential claimants: the MDL is still in early enough stages that new cases filed now can be included in any eventual settlement. Claimants who wait too long risk being barred by statutes of limitations or arriving after a settlement fund has been structured and closed. The August 4, 2026 bellwether deadline marks the beginning of the litigation’s active trial-preparation phase — the moment when both sides start investing heavily in individual cases. Filing before that phase advances further positions claimants to be part of the compensation process when resolution ultimately comes.
Frequently Asked Questions About the AngioDynamics Port Catheter Lawsuit
What AngioDynamics port devices are included in the MDL 3125 lawsuit?
MDL 3125 covers three implantable port catheter products: the SmartPort CT Titanium Port, the Vortex Port, and the Xcela Plus Port, all manufactured by AngioDynamics, Inc. or its subsidiary Navilyst Medical, Inc. These devices were widely used in cancer patients receiving chemotherapy and other patients requiring long-term intravenous access. If you are unsure which device you received, your hospital implant records or the surgical operative report will identify the manufacturer and product name.
What injuries qualify for the AngioDynamics port catheter lawsuit?
Qualifying injuries in the AngioDynamics port catheter lawsuit include catheter fracture and fragment migration to the heart or lungs, catheter-related bloodstream infections (CRBSIs), sepsis requiring hospitalization, venous thrombosis, pulmonary embolism, and wrongful death resulting from any of these complications. The MDL’s bellwether structure specifically requires a mix of infection, thrombosis, and fracture cases, reflecting the range of injuries plaintiffs are alleging across the 391 cases currently pending.
How does the AngioDynamics MDL compare to the Bard PowerPort lawsuit?
Both litigations involve implantable port catheters used primarily in cancer patients and allege similar failure modes including fracture, migration, infection, and thrombosis. The Bard PowerPort MDL 3081 in Arizona is significantly larger with 3,564 cases as of July 2026, while MDL 3125 has 391 cases. Bard’s first bellwether trial resulted in a defense verdict on an infection-only case in May 2026, suggesting that fracture and migration cases — where mechanical device failure is more directly demonstrable — may be stronger trial vehicles. AngioDynamics’ first bellwether trial is not expected until mid-2028.
How long do I have to file an AngioDynamics port catheter lawsuit?
Statutes of limitations for medical device product liability claims typically run two to three years from the date you discovered, or reasonably should have discovered, that your injury was connected to the implanted port catheter. Because some injuries like catheter fractures or thrombosis may not be discovered immediately after they occur, the clock often starts running from the date of diagnosis rather than implant date. Given that the MDL is actively accepting new filings and is still in early stages as of July 2026, potential claimants should act promptly to preserve their legal rights.
When can AngioDynamics port catheter lawsuit plaintiffs expect compensation?
No settlements have been announced in MDL 3125 as of July 2026. Based on the current procedural schedule — bellwether pool finalized by December 2026, first trial projected for mid-2028 — mass tort attorneys estimate that a global AngioDynamics port catheter lawsuit settlement is unlikely before 2028 to 2029 at the earliest. The bellwether trial results will heavily influence settlement negotiations, as they provide both sides with data about how juries evaluate the evidence. Filing a claim now ensures you are positioned to participate in any eventual settlement fund.
Legal Disclaimer: The content on this page is provided for general informational purposes only and does not constitute legal advice; no attorney-client relationship is formed by reading this article.
Related reading: Ozempic & GLP-1 Agonist Gastrointestinal Injury: Damages Calculator & Lawsuit Settlement Values 2026
Related reading: The Vocational Expert In A Wrongful Death Case: How One Witness Builds The Earning Capacity Number Every Calculator Starts With
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.